279 related articles for article (PubMed ID: 30982843)
1. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial.
Pijpers JA; Kies DA; Louter MA; van Zwet EW; Ferrari MD; Terwindt GM
Brain; 2019 May; 142(5):1203-1214. PubMed ID: 30982843
[TBL] [Abstract][Full Text] [Related]
2. Behavioural intervention in medication overuse headache: A concealed double-blind randomized controlled trial.
Pijpers JA; Kies DA; van Zwet EW; Rosendaal FR; Terwindt GM
Eur J Neurol; 2022 May; 29(5):1496-1504. PubMed ID: 35064733
[TBL] [Abstract][Full Text] [Related]
3. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
4. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
Freitag FG; Diamond S; Diamond M; Urban G
Headache; 2008 Feb; 48(2):201-9. PubMed ID: 18042229
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxins for the prevention of migraine in adults.
Herd CP; Tomlinson CL; Rick C; Scotton WJ; Edwards J; Ives N; Clarke CE; Sinclair A
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD011616. PubMed ID: 29939406
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
Diener HC; Marmura MJ; Tepper SJ; Cowan R; Starling AJ; Diamond ML; Hirman J; Mehta L; Brevig T; Sperling B; Cady R
Headache; 2021 Jan; 61(1):125-136. PubMed ID: 33314079
[TBL] [Abstract][Full Text] [Related]
7. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study.
Yu S; Zhou J; Luo G; Xiao Z; Ettrup A; Jansson G; Florea I; Ranc K; Pozo-Rosich P
BMC Neurol; 2023 Dec; 23(1):441. PubMed ID: 38102535
[TBL] [Abstract][Full Text] [Related]
9. [Botulinum toxin type A (Relatox) in transition from medication overuse to non-overuse status in patients with chronic migraine: a subgroup analysis of phase IIIb randomized single-blind multicenter active-controlled parallel-group trial].
Artemenko AR; Abramov VG; Bozhenkina TV; Konovalova ZN; Korenko AN; Krasavina DA; Kurenkov AL; Latysheva NV; Naprienko MV; Orlova OR; Filatova EG; Shevchenko VS; Iakovleva PN
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(11):64-74. PubMed ID: 37994890
[TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
11. Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results of a long-term treatment.
Grazzi L
Neurol Sci; 2017 May; 38(Suppl 1):141-143. PubMed ID: 28527077
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
Giri S; Tronvik E; Linde M; Pedersen SA; Hagen K
Cephalalgia; 2023 Apr; 43(4):3331024231156922. PubMed ID: 36856015
[TBL] [Abstract][Full Text] [Related]
13. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study.
Bøe MG; Mygland A; Salvesen R
Neurology; 2007 Jul; 69(1):26-31. PubMed ID: 17475943
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
15. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
16. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.
Magid M; Reichenberg JS; Poth PE; Robertson HT; LaViolette AK; Kruger TH; Wollmer MA
J Clin Psychiatry; 2014 Aug; 75(8):837-44. PubMed ID: 24910934
[TBL] [Abstract][Full Text] [Related]
17. [Botulinum toxin type A (Relatox) in the treatment of chronic migraine in adults: results of phase IIIb, randomized, one-blind, multicenter, active-controlled, parallel-group trial].
Artemenko AR; Abramov VG; Konovalova ZN; Korenko AN; Krasavina DA; Kurenkov AL; Latysheva NV; Naprienko MV; Orlova OR; Filatova EG; Shevchenko VS; Yakovleva PN
Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(5):89-99. PubMed ID: 37315247
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
[TBL] [Abstract][Full Text] [Related]
19. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
Marmura MJ; Diener HC; Cowan RP; Tepper SJ; Diamond ML; Starling AJ; Hirman J; Mehta L; Brevig T; Cady R
Headache; 2021 Oct; 61(9):1421-1431. PubMed ID: 34551130
[TBL] [Abstract][Full Text] [Related]
20. Regional Targeted Subcutaneous Injection of Botulinum Neurotoxin Type A in Refractory Chronic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.
Bono F; Mazza MR; Magro G; Spano G; Idone G; Laterza V; Tedeschi D; Pucci F; Gambardella A; Sarica A
Toxins (Basel); 2023 May; 15(5):. PubMed ID: 37235358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
